Lucia Masarova, MD
Medical Oncology · Houston, TXNPI 1932583119
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $12,919 of the $21,166 with a category attached, or 61.0%. GSK accounts for 67.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $17,140 and has fallen 98.2% since, to $309 in 2025.
Across 33 payments — averaging $641.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$14K
- Pharmaessentia USA Corporation$3K
- Morphosys, US Inc.$2K
- Jazz Pharmaceuticals Inc.$540
- Bristol Myers Squibb$341
- CTI Biopharma Corp.$247
- plus $389 from 3 others
Across 181 payments — averaging $164,191 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$27.1M
- Pharmaessentia USA Corporation$1.7M
- Incyte Corporation$846K
- NS Pharma, Inc.$75K
What the payments were for
- Consulting fees$4,95523%
- Speaking & faculty fees$1,1605%
- Travel & lodging$12,91961%
- Food & beverage$2,13210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $14,294 |
| Pharmaessentia USA Corporation | 5 | $2,986 |
| Morphosys, US Inc. | 2 | $2,369 |
| Jazz Pharmaceuticals Inc. | 4 | $540 |
| Bristol Myers Squibb | 2 | $341 |
| CTI Biopharma Corp. | 2 | $247 |
| Servier Pharmaceuticals LLC | 1 | $155 |
| Sobi, Inc | 2 | $151 |
| AstraZeneca | 1 | $83 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,166 in reported general payments places this provider in the 70th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 16 | $77,483 |
| ValacyclovirValacyclovir Hcl | 28 | $498 |
| Hydroxyurea | 12 | $175 |
| Levofloxacin | 16 | $143 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.